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Background: A fixed dose combination of isosorbide dinitrate plus hydralazine (FDC I/H) reduced mortality in black patients with moderate to 
severe heart failure in the African-American Heart Failure Trial (A-HeFT). We further examined its effect on hospital readmissions.
Methods: A total of 1050 black patients with New York Heart Association class III or IV heart failure were randomized to FDC I/H or placebo, in 
addition to standard therapy including beta-blockers (83%), diuretics (92%) and ACEI or ARB (93%). The trial lasted 1.5 years, during which time 
86 patients died, and 423 were hospitalized a total of 993 times (43% for heart failure, 34% non-cardiac, 23% other). Rehospitalization time was 
calculated as the days between hospital discharge and readmission. The effect of FDC I/H was compared to placebo using multivariable linear and 
logistic regression, adjusting for baseline differences in clinical characteristics and medications.
Results: Patients who were hospitalized had more baseline comorbidities including chronic kidney disease, previous myocardial infarction, COPD 
and atrial fibrillation. When examining all-cause related hospitalizations, FDC I/H significantly increased the average time to rehospitalization 
(130 vs. 100 days, P=0.041). There was no significant difference in the duration of hospital stay (Placebo 5.9 ± 7.4 days, FDC I/H 5.0 ± 8.0 days, 
P=0.514). In the placebo group, 68 (31%) patients were rehospitalized within 30 days of discharge at least once, compared to 43 (21%) in the 
FDC I/H group. This beneficial effect remained significant after adjusting for baseline comorbidities, medications, left ventricular ejection fraction 
and demographic factors in a multivariable logistic regression analysis (OR 0.59, 95% CI 0.37 - 0.93, P=0.024). When examining only heart-failure 
related hospitalizations, there was a similar although not statistically significant trend (OR 0.64, 95% CI 0.36 - 1.14, P=0.133).
Conclusions: The addition of FDC I/H to standard therapy significantly increased the time between hospital discharge and readmission, and 
resulted in approximately 40% reduction in 30-day rehospitalization rates.
